Insulin — Detemir — Half-Life, Dosing & Protocol Guide

Also known as: Levemir, detemir insulin

Pharmacokinetics & Mechanism

Insulin detemir (Levemir) has a subcutaneous terminal half-life of 5–7 hours (dose-dependent), established in the FDA Levemir prescribing label (NDA 021536). Myristoyl (C14) fatty acid conjugation at B29Lys enables greater than 98% reversible albumin binding → controlled slow release from the subcutaneous albumin depot, extending duration to 12–24 hours. The albumin buffering reduces glycaemic variability compared to NPH. Associated with less weight gain than NPH in comparative clinical trials, possibly attributable to central satiety effects.

Track Insulin — Detemir in Halflife

The Halflife app models your Insulin — Detemir concentration curve in real time — see exactly when your dose peaks, when it troughs, and how it overlaps with other compounds in your stack. All stored on-device, no account required.